TrialFrontiers in immunology2024

Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.

Mostafa Ghanei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.